LAM launches wound gel in Latin America:
This article was originally published in Clinica
Transdermal drug delivery systems specialist LAM Pharmaceutical today announced the launch of its IPM Wound Gel. Distributors and healthcare professionals from Argentina, Brazil, Costa Rica, Ecuador, El Salvador and Panama have expressed an interest in the gel, claims the Lewiston, New York-based company. It features LAM's Ionic Polymer Matrix (IPM) technology - "a combination of electrically charged and non-charged molecules with wound-healing properties". LAM has offices in Canada (Toronto) and China (Beijing).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.